Congratulations! EClinCloud eCOA Supports the Approval of ArkBio's New ADHD Drug Aizhida® in China

January 6, 2026 — Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that the NMPA has approved the new drug application for serdexmethylphenidate and dexmethylphenidate capsules (Aizhida®) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years and those older than 6 years.
In March 2025, ArkBio announced the successful completion of the Phase III clinical study of Aizhida® for ADHD in China. The study, co-led by Beijing Anding Hospital, Capital Medical University, and Peking University Sixth Hospital across 8 clinical trial sites nationwide, was designed to evaluate the efficacy, safety, and tolerability of oral Aizhida® in pediatric trial participants with ADHD aged 6 to 12 years.
EClinCloud partnered with ArkBio in the Aizhida® Phase III clinical study to provide an integrated eCOA solution and end-to-end service support, helping the study team achieve high-quality data capture and management, improve study efficiency and the reliability of endpoint assessment, and accelerate new drug development and delivery.
EClinCloud extends sincere congratulations to its partner on this achievement and looks forward to working together in the future to advance new drug development to benefit more patients!


